Get the Stockscreener App
14.73
18.89%
-3.43
Pre-market:
14.90
0.17
+1.15%
Yd Bio Ltd stock is traded at $14.73, with a volume of 130.47K.
It is down -18.89% in the last 24 hours and up +0.00% over the past month.
YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.
See More
Previous Close:
$18.16
Open:
$15.86
24h Volume:
130.47K
Relative Volume:
8.88
Market Cap:
$1.04B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$14.36
$17.90
1-Week Range:
$12.51
$23.94
52-Week Range:
$12.51
$23.94
Yd Bio Ltd Stock (YDES) Company Profile
Compare YDES with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
YDES
Yd Bio Ltd
|
14.73 | 956.80M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Yd Bio Ltd Stock (YDES) Latest News
Why Did YD Bio Plunge 14.37% Despite Revenue Growth? - AInvest
Macy's Increases FY2025 Outlook, Joins REV Group, HealthEquity, Alphabet and Wellness And Other Big Stocks Moving Higher On Wednesday - Benzinga
YD Bio Limited shares rise 7.33% premarket after being added to NASDAQ. - AInvest
YD Bio Stock Fuels Retail-Trader Excitement After Nasdaq Listing Through Breeze SPAC Deal - Asianet Newsable
YD Bio Limited Announces Closing of Business Combination - citybiz
YDESBreeze Holdings Latest Stock News & Market Updates - Stock Titan
YD Bio's Nasdaq Debut: A Strategic SPAC Merger Positions the Biotech Innovator for High-Growth Catalysts - AInvest
Nasdaq: YD Bio Completes Merger With Breeze - AInvest
YD Bio Shares to Begin Trading on Nasdaq After Completing Merger With Breeze - MarketScreener
YD Bio Limited begins trading on Nasdaq under YDES, YDESW symbols. - AInvest
YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market - GlobeNewswire
Taiwan Biotech YD Biopharma Secures Path to Nasdaq Through Breeze Holdings SPAC Merger Approval - Stock Titan
Biocon Biologics and Yoshindo expand access to Ustekinumab Biosimilar in Japan - BioSpectrum Asia
Reproductive adaptation of Astyanax mexicanus under nutrient limitation - ScienceDirect.com
Breeze Holdings Acquisition Corp. Announces Definitive Agreement to Merge with YD Biopharma Limited - GlobeNewswire
MARKET DATA - The Wall Street Journal
US Share Prices - London South East
From neural tube to spinal cord: The dynamic journey of the dorsal neuroepithelium - ScienceDirect.com
The heparan sulfate modification enzyme, Hs6st1, governs Xenopus neuroectodermal patterning by regulating distributions of Fgf and Noggin - ScienceDirect.com
A fishy tail: Insights into the cell and molecular biology of neuromesodermal cells from zebrafish embryos - ScienceDirect.com
Hormone-related genes heterochronically and modularly regulate neotenic differentiation in termites - ScienceDirect.com
Heads or tails: making the spinal cord - ScienceDirect.com
A novel gene trap line for visualization and manipulation of erbb3b+ neural crest and glial cells in zebrafish - ScienceDirect.com
Transcriptional and epigenetic regulation of temporal patterning in neural progenitors - ScienceDirect.com
E-liquids and vanillin flavoring disrupts retinoic acid signaling and causes craniofacial defects in Xenopus embryos - ScienceDirect.com
YAP/TAZ maintain the proliferative capacity and structural organization of radial glial cells during brain development - ScienceDirect.com
Multi-tissue patterning drives anterior morphogenesis of the C. elegans embryo - ScienceDirect.com
WNT signalling supported by MEK/ERK inhibition is essential to maintain pluripotency in bovine preimplantation embryo - ScienceDirect.com
U.S. STOCKS - The Wall Street Journal
Markets Today — Quotes, Charts, and Events - TradingView
Ovaries of the white worm (Enchytraeus albidus, Annelida, Clitellata) are composed of 16-celled meroistic germ-line cysts - ScienceDirect.com
Volvox: A simple algal model for embryogenesis, morphogenesis and cellular differentiation - ScienceDirect.com
Msxb is a core component of the genetic circuitry specifying the dorsal and ventral neurogenic midlines in the ascidian embryo - ScienceDirect.com
The causes of repeated genetic evolution - ScienceDirect.com
Doublesex establishes sexual dimorphism in the Drosophila central nervous system in an isoform-dependent manner by directing cell number - ScienceDirect.com
Yd Bio Ltd Stock (YDES) Financials Data
There is no financial data for Yd Bio Ltd (YDES). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.75%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):